scholarly journals ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study

2021 ◽  
Author(s):  
Dominic Beale ◽  
Jeremy Dennison ◽  
Malcolm Boyce ◽  
Francesca Mazzo ◽  
Naoki Honda ◽  
...  
Keyword(s):  
Human Study ◽  
Pharmacokinetics And Pharmacodynamics

scholarly journals A first‐in‐human study of KMRC011, a potential treatment for acute radiation syndrome, to explore tolerability, pharmacokinetics, and pharmacodynamics

2021 ◽  
Author(s):  
Eunsol Yang ◽  
Hyejung Choi ◽  
Jin‐Sol Park ◽  
Young‐Woock Noh ◽  
Chi‐Min Choi ◽  
...  
Keyword(s):  
Human Study ◽  
Acute Radiation ◽  
Potential Treatment ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Acute Radiation Syndrome

scholarly journals First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects

2018 ◽  
Vol 84 (5) ◽  
pp. 876-887 ◽  
Author(s):  
Vidya Perera ◽  
Joseph M. Luettgen ◽  
Zhaoqing Wang ◽  
Charles E. Frost ◽  
Cynthia Yones ◽  
...  
Keyword(s):  
Small Molecule ◽  
Healthy Subjects ◽  
Human Study ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Factor Xia

scholarly journals Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

2015 ◽  
Vol 22 (4) ◽  
pp. 827-836 ◽  
Author(s):  
Amita Patnaik ◽  
Glen J. Weiss ◽  
John E. Leonard ◽  
Drew Warren Rasco ◽  
Jasgit C. Sachdev ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Human Study ◽  
Advanced Solid Tumors ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Semaphorin 4D

First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies

2015 ◽  
Vol 33 (5) ◽  
pp. 1048-1057 ◽  
Author(s):  
Kyu-pyo Kim ◽  
Seong Joon Park ◽  
Jeong-Eun Kim ◽  
Yong Sang Hong ◽  
Jae-Lyun Lee ◽  
...  
Keyword(s):  
Hdac Inhibitor ◽  
Human Study ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Solid Malignancies

Single-Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen-Activated Protein Kinase Inhibitor: A First-in-Human Study

2003 ◽  
Vol 43 (4) ◽  
pp. 406-413 ◽  
Author(s):  
Dolly A. Parasrampuria ◽  
Peter de Boer ◽  
Daksha Desai-Krieger ◽  
Andrew T. Chow ◽  
C. Richard Jones
Keyword(s):  
Single Dose ◽  
Protein Kinase ◽  
Kinase Inhibitor ◽  
Human Study ◽  
Protein Kinase Inhibitor ◽  
Mitogen Activated Protein Kinase ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Mitogen Activated Protein

scholarly journals Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist

2018 ◽  
Vol WCP2018 (0) ◽  
pp. PO1-11-13
Author(s):  
Kenya Nakai ◽  
Sanae Yasuda ◽  
Min-Kun Chang ◽  
Mark Matijevic ◽  
Shannon Mcgrath ◽  
...  
Keyword(s):  
Human Study ◽  
Toll Like Receptor ◽  
Pharmacokinetics And Pharmacodynamics

First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma

2019 ◽  
Vol 83 (6) ◽  
pp. 1057-1063 ◽  
Author(s):  
Christophe Massard ◽  
Jean-Charles Soria ◽  
Jürgen Krauss ◽  
Michael Gordon ◽  
Albert Craig Lockhart ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Human Study ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document